Connor Clark & Lunn Investment Management Ltd. Increases Stock Position in Chimerix, Inc. (NASDAQ:CMRX)

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Chimerix, Inc. (NASDAQ:CMRX) by 24.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 429,513 shares of the biopharmaceutical company’s stock after buying an additional 84,801 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Chimerix were worth $1,495,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of CMRX. Stoneridge Investment Partners LLC boosted its position in Chimerix by 22.5% during the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 8,134 shares in the last quarter. Bender Robert & Associates bought a new stake in Chimerix during the fourth quarter valued at about $37,000. Charles Schwab Investment Management Inc. purchased a new position in Chimerix in the fourth quarter valued at about $183,000. Palumbo Wealth Management LLC bought a new position in Chimerix in the fourth quarter worth about $221,000. Finally, Valeo Financial Advisors LLC lifted its position in shares of Chimerix by 78.8% during the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock valued at $509,000 after buying an additional 64,420 shares during the last quarter. Institutional investors own 45.42% of the company’s stock.

Insider Transactions at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last ninety days, insiders sold 20,760 shares of company stock worth $91,175. Company insiders own 13.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Jefferies Financial Group reaffirmed a “hold” rating and issued a $8.50 price objective (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th. Wedbush reaffirmed a “neutral” rating and issued a $8.55 price target (up from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. HC Wainwright reiterated a “neutral” rating and set a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a report on Wednesday, March 5th. Finally, StockNews.com assumed coverage on Chimerix in a research report on Saturday, March 15th. They issued a “hold” rating for the company.

Chimerix Stock Performance

NASDAQ:CMRX opened at $8.48 on Thursday. The company’s 50 day moving average is $5.14 and its two-hundred day moving average is $2.73. The company has a market cap of $762.66 million, a PE ratio of -9.02 and a beta of 0.32. Chimerix, Inc. has a twelve month low of $0.75 and a twelve month high of $8.49.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.